

# **APPENDIX TO DEFENDANTS' OPENING POST TRIAL BRIEF**

**APPENDIX OF EXHIBITS**

<b>Exhibit</b>	<b>Description</b>
DTX 0007	Certified U.S. Patent No. 7,070,959
DTX 0013	Certified U.S. Patent No. 10,406,226
DTX 0019	Certified U.S. Patent No. 10,973,879
DTX 0204	James A. Dixon et al., VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration, 18(10) Expert Opinion on Investigational Drugs 1573 (2009)
DTX 0207	2004-01-30 Cedarbaum email re VEGF Trap AMD Press Release
DTX 0210	2005-03-03 Simitchieva email re Release of results AVASTIN in WET AMD
DTX 0216	2006-03-21 Cedarbaum email re Final ASRS 0508 Abstract
DTX 0218	2006-05-09 Cedarbaum email re Rosnfeld's Lucentis PRONTO press release
DTX 0231	2007-08-12 Ingerman email re NCT00509795.htm
DTX 0232	CLEAR-IT 2: Interim Results Poster
DTX 0234	2007-05-07 Poole email to Yancopoulos re ARVO, with attachments
DTX 0710	2004-03-01 Email from J. Cedarbaum re Extra-ocular delivery of Lucentis
DTX 0711	2004-12-08 Email from N. Dugrenier re FW: Specification for Intravitreal VEGF trap.
DTX 0714	2005-01-27 Email from N. Stahl re Lucentis-itv pk
DTX 0716	2005-04-12 Email from E. Furfine re FW: avastatin amea discussion.pdf
DTX 0718	2005-08-18 Email from K. Frye re Avastatin & Macugen formulations
DTX 0722	2006-03-21 Email from K. DeWald re FW: Sucrose VGT formulation help
DTX 0725	2006-05-08 Email from K. Graham re VEGF Trap formulations for ITV
DTX 0726	U.S. Patent Application WO 2006/047325 A1
DTX 0728	Christine Wulff et al., Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2, 143(7) Endocrinology 2797 (2002)
DTX 0729	Hamish M. Fraser et al., Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function, 90(2) Journal of Clinical Endocrinology & Metabolism 1114 (2005)
DTX 0730	US Patent Application Publication No. US 2004/0197324 A1
DTX 0900	2023-01-12 Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-17)
DTX 0917	2010-11-22 Email from news desk re Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration
DTX 2035	"Ongoing Treatment for Patients with Neovascular AMD", Retinal Physician Article (2007-10-01)

<b>Exhibit</b>	<b>Description</b>
DTX 2040	PAT Survey Policies and Guidelines, dated 2010
DTX 2062	U.S. Patent No. 7,374,758, dated 05-20-2008
DTX 2264	Avery et al., "Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration", Ophthal 113(3):363-372 (2006)
DTX 2265	Gaudreault et al., "Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration", Inv. Ophthal & Vis. Sci. 46(2):726-733 (2005)
DTX 2730	U.S. Patent No. 7,303,747
DTX 2733	Geeta A. Lalwani et al., Anti-VEGF Therapy in Diabetic Macular Edema: An Overview of New Agents Under Investigation, RETINA TODAY 45 (Sept. 2009)
DTX 2751	Saishin paper
DTX 3040	Lucentis Label 2006
DTX 3058	Rosenfeld 2005
DTX 3102	Do 2009
DTX 3198	Regeneron Press Release Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
DTX 3316	Eylea Label 11-2011
DTX 3501	959 Patent Petition for Patent Term Extension
DTX 3510	Avastin PI
DTX 3549	Holash, VEGF-Trap: A VEGF blocker with potent antitumor effects dated 7/2/02 (received for review 4/19/02) (also admitted into evidence as DTX 2745)
DTX 3588	Remington Vol 2 (ophthalmic solutions) 1995 (Hecht)
DTX 3592	Rudge
DTX 3610	US Publication 2003 0113316A1 Kaisheva I
DTX 3619	WO 2000 075319A1 Papadopoulos
DTX 4008	Adis R&D Profile, Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye, 9 Drugs R&D 261 (2008) ("Adis")
DTX 4013	Ziad F. Bashshur et al., Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study, 145 Am. J. Ophthalmology 249 (2008)
DTX 4041	Napoleone Ferrara & Robert S. Kerbel, Angiogenesis as a Therapeutic Target, 438 Nature 967 (2005)
DTX 4116	U.S. Patent No. 7,306,799
DTX 4120	U.S. Patent No. 7,531,173
DTX 4121	U.S. Patent Application Publication No. 2006/0217311 A1 ("Dix")

<b>Exhibit</b>	<b>Description</b>
DTX 4135	Mylan Pharms. Inc. v. Regeneron Pharms., Inc., IPR2021-00881 (P.T.A.B), Paper 94 (Nov. 9, 2022) (“FWD”)
DTX 4229	U.S. Patent Application Publication No. US2005/0175610 A1
DTX 4900	U.S. Patent No. 7,303,746
DTX 4903	U.S. Patent No. 7,374,757
DTX 4956	Regeneron Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2004
DTX 4957	Regeneron Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2005
DTX 4986	Second Amendment to Collaboration Agreement, dated 1/7/05, available at <a href="https://www.sec.gov/Archives/edgar/data/872589/000095012305000248/y04663exv10w1.htm">https://www.sec.gov/Archives/edgar/data/872589/000095012305000248/y04663exv10w1.htm</a>
DTX 5036	REMICADE® Label
DTX 5037	XOLAIR® Label
DTX 5038	RAPTIVA® Label
DTX 5040	HERCEPTIN® Label
DTX 5073	BLA No. 125387, 2.7.1 Summary of Biopharmaceutic Studies and Associate Analytical Methods
DTX 5385	Internal Regeneron R&D document
DTX 5429	Ruti Sella et al., Subconjunctival Aflibercept for the Treatment of Formed Corneal Neovascularization, 47(7) Eye & Contact Lens 180 (2021)
DTX 5430	Abtin Shahlaee et al., Translational and Clinical Advancements in Management of Proliferative Vitreoretinopathy, 33(3) Current Opinion in Ophthalmology 219 (2022)
DTX 5431	Toktam Shahraki et al., Pterygium: An Update on Pathophysiology, Clinical Features, and Management, 13 Therapeutic Advances in Ophthalmology 1 (2021)
DTX 8180	Heier et al., “The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing”, Am. Acad. Ophthal. 118(6): 1098-1106
DTX 8194	Provisional application No. 60/665,125 (“Dix Provisional”)
DTX 8206	United States Patent Application Publication No. US20050163798A1
DTX 8207	United States Patent Application Publication No. US20050245447A1
DTX 8208	United States Patent Application Publication No. US20050260203A1
DTX 8209	United States Patent Application Publication No. US20060030529A1
DTX 9006	Aflibercept: Drugs of the Future
DTX 9030	Subconjunctival Bevacizumab Immediately After Excision of Primary Pterygium: The First Clinical Trial
DTX 9031	Prevention of Recurrent Pterygium with Topical Bevacizumab 0.05% Eye Drops

<b>Exhibit</b>	<b>Description</b>
DTX 9032	A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study
DTX 9033	Efficacy of Intravitreal Injection of Bevacizumab in Vitrectomy for Patients with Proliferative Vitreoretinopathy Retinal Detachment
DTX 9035	Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy
DTX 9036	"Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration" by Dr. Avery (With Date Stamp)
DTX 9038	Ziv-Aflibercept as a Possible Alternative to Aflibercept by Chang, J.S., et al.,
PTX-0001	Certified U.S. Patent No. 10,888,601
PTX-0002	Certified U.S. Patent No. 11,084,865
PTX-0003	Certified U.S. Patent No. 11,253,572
PTX-1758	PCT Patent Publication No WO2005/102303
PTX-1825	Amendment 7 0 to Stability Study Protocol VGFT-SS207
PTX-1832	Chang 2002 - Chang et al, Practical Approaches to Protein Formulation Development, in Rational Design of Stable Protein Formulations 1, 14 (J F Carpenter & M C Manning eds, 2002)
PTX-3348	International Journal of Retina and Vitreous